# Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)

> **NCT01263314** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 16 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** MK-8266
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01263314
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-01
- **Primary completion:** 2011-02-01
- **Final completion:** 2011-03-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263314, "Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01263314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*